During the corresponding time, Biora Therapeutics Inc sequentially revenue fell by -89.94 %. While revenue at the Biora Therapeutics Inc 's corporate clients
Biora Therapeutics Inc's Comment on Sales, Marketing and Customers
The company requires that device operation be performed only by qualified personnel and emphasizes customer training. Its products are subject to regulatory requirements in the United States, the European Union, and other jurisdictions. In the EU, the company complies with the EU Medical Device Regulation (EU MDR), which governs marketing and sales. In the U.S., drugs and biologics must receive approval from the Food and Drug Administration (FDA) through a New Drug Application (NDA) or Biologics License Application (BLA) prior to marketing. This approval process involves preclinical testing, submission of an Investigational New Drug (IND) application, ethics committee approvals, and manufacturing in accordance with good manufacturing practices. The company operates in the U.S., the EU, and other international markets subject to these regulatory frameworks.
Revolutionizing Colon Therapeutics: Biora Therapeutics NaviCap Platform Shows Promising Clinical ResultsBiora Therapeutics, a pioneering healthcare company, recently presented clinical data at Digestive Disease Week 2024, highlighting the remarkable device function of their groundbreaking NaviCap Platform. Four device performance studies conducted by the company demonstrated the platform s ability to deliver therapeutics directly to the colon, even under variable gastrointestinal (GI) conditions. Additionally, Biora Therapeutics achieved positive interim results for their clinical trial of BT-600, further advancing the development of the NaviCap Platform. The successful completion of the Single-Ascending D...
Biora Therapeutics: A Look Ahead at 2024 Catalysts and Revenue ChallengesBiora Therapeutics, a prominent biopharmaceutical company, recently provided insights into its outlook for the year 2024. Exciting developments are expected during this period, including the release of clinical study results for their innovative NaviCap platform and advancements in their pharma partnerships for the BioJet platform. However, the company s financial performance has taken a toll, with a significant decline in revenue.According to reports, Biora Therapeutics Inc witnessed a staggering 98.08% year-on-year decrease in revenue. This decline reflects a worrisome trend for the company, as it struggled to maintain its financial s...
Biora Therapeutics Inc., a renowned name in the biopharmaceutical industry, has recently signaled a fresh direction for its endeavors desp...
Biora Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company requires that device operation be performed only by qualified personnel and emphasizes customer training. Its products are subject to regulatory requirements in the United States, the European Union, and other jurisdictions. In the EU, the company complies with the EU Medical Device Regulation (EU MDR), which governs marketing and sales. In the U.S., drugs and biologics must receive approval from the Food and Drug Administration (FDA) through a New Drug Application (NDA) or Biologics License Application (BLA) prior to marketing. This approval process involves preclinical testing, submission of an Investigational New Drug (IND) application, ethics committee approvals, and manufacturing in accordance with good manufacturing practices. The company operates in the U.S., the EU, and other international markets subject to these regulatory frameworks.
Sources:
Biora Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biora Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biora Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
